WAAG
GANX icon

Wealth Alliance Advisory Group’s Gain Therapeutics GANX Stock Holding History

Wealth Alliance Advisory Group’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,502
Closed -$60.3K – 177
2023
Q1 		$60.3K Sell
12,502
-6,249
-33% -$25.5K 0.02% 161
2022
Q4 		$58.7K Sell
18,751
-6,249
-25% -$19.5K 0.02% 163
2022
Q3 		$82K Buy
+25,000
New +$93.9K 0.04% 149

Other funds holding GANX

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Wealth Alliance Advisory Group's GANX Position: Q2 2023 in Review

Wealth Alliance Advisory Group sold out of Gain Therapeutics (GANX) in Q2 2023, closing a stake of 12,502 shares — an estimated $60.3K sold.

Wealth Alliance Advisory Group first reported a position in GANX in Q3 2022 and held it in 3 quarters. The position peaked at $82K in Q3 2022. 24 funds tracked by Wall St. Rank hold GANX as of Q2 2023.

  • Wealth Alliance Advisory Group reported no remaining Gain Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Wealth Alliance Advisory Group sold 12,502 Gain Therapeutics shares in Q2 2023, an estimated $60.3K.
  • Wealth Alliance Advisory Group first reported a position in Gain Therapeutics in Q3 2022 and held it in 3 quarters.
  • Wealth Alliance Advisory Group's Gain Therapeutics position peaked at $82K in Q3 2022.
  • 24 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2023.

Based on Wealth Alliance Advisory Group's 13F filing for Q2 2023, filed 13 Jul 2023.